Of interest, strong (IRS ≥ 6) NDRG2 immunohistochemical staining was significantly associated with low HER2-receptor expression (0–1+) concordant to abundant transcriptional NDRG2 mRNA expression in breast carcinomas with low HER2-expression level (Table 2). This evidence concerns the gene ERBB2 and breast carcinoma.